Human malignant mesothelioma responded as well to the antitumour effects of TRAIL-expressing MSCs derived from human bone marrow, and the inflammatory tumour environment in vivo was successfully reduced after their administration [91]. The gene discussed is TNFSF10; the disease is malignant mesothelioma.